It highlights significant gains made within the combat in opposition to hepatitis B and C, which collectively account for 95 per cent of all hepatitis-related deaths worldwide.
These infections claimed 1.34 million lives in 2024. In the meantime, transmission continues at a fee of some 1.8 million infections yearly – or greater than 4,900 instances daily.
Viral infections
Hepatitis B is a viral an infection that assaults the liver. It may be unfold by contact with contaminated physique fluids similar to blood, saliva, vaginal fluids and semen, or handed from mom to child.
Illness might be acute or power, with power an infection elevating threat of demise from cirrhosis and liver most cancers.
Hepatitis C is an irritation of the liver brought on by a virus of the identical title. Transmission is unfold by publicity to contaminated blood from unsafe injections, similar to sharing needles and syringes or unscreened blood transfusions.
A decade of features
The 2026 Global Hepatitis Report paperwork progress since 2015. For instance, new hepatitis B infections have declined by 32 per cent whereas hepatitis C-related deaths have dropped by 12 per cent.
Hepatitis B prevalence amongst kids underneath 5 has additionally fallen to 0.6 per cent, with 85 international locations attaining or surpassing the 2030 goal of decreasing prevalence to 0.1 per cent.
Whereas these advances replicate sustained and coordinated worldwide motion in the direction of viral hepatitis elimination targets adopted on the 2016 World Health Assembly, present charges are inadequate to fulfill all 2030 elimination targets.
Pressing scale-up wanted
WHO Director-Common Tedros Adhanom Ghebreyesus stated international locations have proven that “eliminating hepatitis just isn’t a pipedream,” however efforts should speed up.
“Many individuals stay undiagnosed and untreated as a result of stigma, weak well being programs and inequitable entry to care,” he stated.
“Whereas we’ve the instruments to eradicate hepatitis as a public well being risk, pressing scale-up of prevention, prognosis and remedy is required if the world is to fulfill the 2030 targets.”
Stopping hepatitis B an infection by immunization in infancy considerably reduces power infections and instances of liver most cancers and cirrhosis in maturity.
Hundreds of thousands affected
The report estimates that 287 million folks – roughly 3 per cent of the worldwide inhabitants – had been residing with power hepatitis B or C an infection in 2024.
Though the WHO African Area accounted for 68 per cent of recent hepatitis B infections, solely 17 per cent of newborns there obtained a birth-dose vaccination.
With regard to hepatitis C, individuals who inject medicine accounted for 44 per cent of recent infections, underscoring the necessity for stronger hurt discount providers and protected injection practices.
Restricted entry to remedy
Entry to remedy additionally stays restricted. Though 240 million folks had been residing with power hepatitis B in 2024, fewer than 5 per cent had been receiving remedy.
Moreover, solely 20 per cent of individuals with hepatitis C have been handled since new efficient remedy grew to become out there in 2015.
Restricted entry to prevention and care continues to drive mortality. In 2024, roughly 1.1 million folks died from hepatitis B and 240,000 from hepatitis C, primarily as a result of liver cirrhosis and liver most cancers.
Ten international locations in Asia and Africa – Bangladesh, China, Ethiopia, Ghana, India, Indonesia, Nigeria, the Philippines, South Africa and Viet Nam – accounted for almost 70 per cent of hepatitis B associated deaths worldwide that 12 months.
Hepatitis C-related deaths are extra geographically dispersed. In 2024, 10 international locations accounted for 58 per cent of international instances: China, India, Indonesia, Japan, Nigeria, Pakistan, Russia, South Africa, america and Viet Nam.
A hepatitis C take a look at is ready for a consumer at Ozone Basis in Bangkok, Thailand. (file)
Confirmed options exist
Regardless of these challenges, WHO pointed to the extremely efficient instruments which can be already out there within the combat in opposition to the illness.
The hepatitis B vaccine is greater than 95 per cent efficient in opposition to each acute and power infections, whereas long-term antiviral remedy may help handle power an infection and forestall extreme liver illness.
On the identical time, short-course remedy for hepatitis C, lasting 8 to 12 weeks, can remedy greater than 95 per cent of instances.
‘Progress is feasible’
Dr. Tereza Kasaeva, Director of WHO’s Division for HIV, TB, Hepatitis and Sexually Transmitted Infections, harassed the necessity to enhance entry to care.
“The info exhibits that progress is feasible but in addition reveals the place we’re falling brief. Each missed prognosis and untreated an infection as a result of power viral hepatitis represents a preventable demise,” she stated.
“International locations should transfer sooner to combine hepatitis providers for folks residing with hepatitis B and C into major care, and to achieve the communities most affected.”
Precedence actions
The report identifies precedence actions to speed up progress, together with scaling up remedy for power hepatitis B an infection notably within the WHO African and Western Pacific areas, and increasing entry to hepatitis C remedy within the Japanese Mediterranean area.
It additionally requires stronger political dedication and elevated financing to develop entry to hepatitis B birth-dose vaccination and medication to forestall mother-to-child transmission.
The report additionally emphasizes the necessity to enhance injection security each in and outdoors healthcare settings, together with by strengthened hurt discount providers for injecting drug customers.
